Kynam Capital Management LP 13D and 13G filings for Celldex Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 5:16 pm Purchase | 2024-12-31 | 13G | Celldex Therapeutics, Inc. CLDX | Kynam Capital Management LP | 5,064,207 7.630% | 2,058,303 (+68.48%) | Filing |
| 2024-02-14 12:52 pm Purchase | 2023-12-31 | 13G | Celldex Therapeutics, Inc. CLDX | Kynam Capital Management LP | 3,005,904 5.500% | 3,005,904 (New Position) | Filing |